EMA Authorised: Nimvastid (rivastigmine) — Krka, d.d., Novo mesto

View source ↗

Summary

EMA authorised Nimvastid (rivastigmine) by Krka for treatment of dementia, including Alzheimer's disease and Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Parkinson Disease

Drugs mentioned

• Nimvastid (rivastigmine)

Snippet

Status: Authorised. Therapeutic area: Dementia;Alzheimer Disease;Parkinson Disease. MAH: Krka, d.d., Novo mesto. Decision date: 15/07/2025